Commitments and Contingencies - Additional Information (Details)		3 Months Ended	6 Months Ended
	May 07, 2019 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 EUR (€) shares	Dec. 31, 2023 USD ($) shares
Commitments And Contingencies [Line Items]
Common stock fair value		$ 5,000	$ 5,000			$ 5,000
Common stock, shares issued | shares		58,601,025	58,601,025		58,601,025	57,970,044
Expenses incurred related to purchase commitments			$ 0	$ 0
Minimum purchase obligation		$ 2,800,000	2,800,000		€ 2,600,000
Minimum
Commitments And Contingencies [Line Items]
Purchase obligation in the first 24-month period		3,200,000	3,200,000		€ 2,900,000
Takeda License
Commitments And Contingencies [Line Items]
Royalty expense		700,000	900,000
Royalty expense included in accrued expenses		$ 700,000	$ 700,000
Takeda License | Takeda
Commitments And Contingencies [Line Items]
License agreement description			On May 7, 2019, the Company entered into the Takeda License. The Company also has the right to sublicense its rights under the agreement, subject to certain conditions. The agreement will remain in effect, on a country-by-country and product-by-product basis, until the later of (i) the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at least one other therapeutically active ingredient, (ii) the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License upon six months’ written notice. The Company and Takeda may terminate the Takeda License in the case of the other party’s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists in challenging, licensed patents.
Agreement expiration term from date of first commercial sale	15 years
Cash consideration paid for license	$ 25,000,000
Common stock fair value	$ 5,900,000
Common stock, shares issued | shares	1,084,000
Warrants exercise price | $ / shares	$ 0.00004613
Initial fair value of warrants	$ 47,900,000
Additional warrant issued | shares	0
Maximum amount payable in sales milestones upon achievement of specified levels of product sales	$ 250,000,000
Warrants expiration date	May 07, 2029
Takeda License | Takeda | Common Stock
Commitments And Contingencies [Line Items]
Warrants issued to purchase shares | shares	7,588,000